GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gensight Biologics SA (XPAR:SIGHT) » Definitions » 12-1 Month Momentum %

Gensight Biologics (XPAR:SIGHT) 12-1 Month Momentum % : -29.72% (As of Apr. 30, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Gensight Biologics 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-04-30), Gensight Biologics's 12-1 Month Momentum % is -29.72%.

The industry rank for Gensight Biologics's 12-1 Month Momentum % or its related term are showing as below:

XPAR:SIGHT's 12-1 Month Momentum % is ranked worse than
58.39% of 1478 companies
in the Biotechnology industry
Industry Median: -20.535 vs XPAR:SIGHT: -29.72

Competitive Comparison of Gensight Biologics's 12-1 Month Momentum %

For the Biotechnology subindustry, Gensight Biologics's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gensight Biologics's 12-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gensight Biologics's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Gensight Biologics's 12-1 Month Momentum % falls into.



Gensight Biologics  (XPAR:SIGHT) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gensight Biologics  (XPAR:SIGHT) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Gensight Biologics 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Gensight Biologics's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Gensight Biologics (XPAR:SIGHT) Business Description

Traded in Other Exchanges
Address
74,rue du Faubourg Saint-Antoine, Paris, FRA, 75012
Gensight Biologics SA is a clinical-stage biotechnology group discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence, and Optogenetics, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. The group focus is on ophthalmology where it develops product candidates to restore eyesight to patients suffering from retinal diseases. The product candidate, LUMEVOQ, was developed using the MTS technology platform and is designed to treat LHON by restoring the function of retinal diseases resulting from mutations.

Gensight Biologics (XPAR:SIGHT) Headlines

No Headlines